Ocrevus Zunovo with Halozyme's Enhanze drug delivery technology is used for the treatment of relapsing multiple sclerosis and ...
Among 282 patients with pediatric-onset MS, 39% started high-efficacy therapy early (at ages 12-17), and 61% started late ...
The FDA approved Ocrevus Zunovo, a subcutaneous formulation of Ocrevus, for adults with relapsing forms of MS and PPMS ...
Ocrelizumab and hyaluronidase is now the first and only twice-yearly subcutaneous injection approved for relapsing multiple ...
Concomitant Lewy body pathology exacerbated cognitive decline in Alzheimer's disease. (Nature Communications) Blocking ...
The Bruton's tyrosine kinase inhibitor tolebrutinib is reportedly the first agent to show benefit in patients with nonrelapsing secondary progressive MS.
A woman with multiple sclerosis (MS) has become the first person in the UK to receive a new "game-changer" 10-minute ...
Subcutaneous administration of ocrelizumab was noninferior to intravenous infusion in the phase 3 OCARINA II trial.
A study presented at ECTRIMS 2024 has identified critical biomarkers that can predict disability worsening in multiple ...
Swiss drug major Roche (RHHBY) announced Monday that the United States Food and Drug Administration has approved OCREVUS ZUNOVO ...
Key biomarkers identified can now predict disability progression in multiple sclerosis, offering potential for more ...
Ocrelizumab also helps to prevent Multiple Sclerosis (MS) relapses. The new method has been used at Swansea Bay University ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback